Literature DB >> 27033692

General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers.

Ozlem Haliloglu1, Burak Dogangun2, Bahar Ozcabi3, Hanife Ugur Kural2, Fatma Ela Keskin1, Hande Mefkure Ozkaya1, Fatma Colkesen Pamukcu2, Elif Bektas2, Burc Cagri Poyraz4, Hakan Buber1, Olcay Evliyaoglu3, Pinar Kadioglu5,6.   

Abstract

PURPOSE: To determine the physical status and intelligence scores of children of acromegalic mothers and to compare them with those of children from mothers without acromegaly.
METHODS: Six women with acromegaly who became pregnant under follow-up between 2010 and 2014 and their 16 children (group A) were assessed and compared with 16 children of healthy women (group B) and 15 children of women with prolactinoma (group C). The physical examinations of children were performed by the department of pediatric endocrinology and intelligence quotient (IQ) testing was undertaken by adult and pediatric psychiatry departments, using appropriate scales for their ages.
RESULTS: Six of the 16 children (girls/boys: 7/9) were born after the diagnosis of acromegaly. Five of the 6 pregnancies occured when the patients were taking somatostatin analogs, none continued taking the drugs during pregnancy. The mean IQ of groups A, B, and C were 106.4 ± 12.5, 105.3 ± 12.5, and 103.2 ± 16.1 respectively (p > 0.05). The mean ages, birth percentiles, recent weight and height standard deviation scores were similar between groups (p > 0.05). Two siblings from group A and 1 child from group B were large for gestational age at birth. At recent follow-up, two children from group A were found tall for their age and one from group C was short for his age and was placed under the care of pediatric endocrinology clinic.
CONCLUSIONS: Pregnancies in acromegaly seems to be uneventful and the general health status and IQ scores of children from women with and without acromegaly were found similar.

Entities:  

Keywords:  Acromegaly; Children; Intelligence quotient; Pregnancy

Mesh:

Year:  2016        PMID: 27033692     DOI: 10.1007/s11102-016-0717-2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  45 in total

1.  Slow-release lanreotide treatment in acromegaly: effects on quality of life.

Authors:  N Sonino; E Scarpa; A Paoletta; F Fallo; M Boscaro
Journal:  Psychother Psychosom       Date:  1999       Impact factor: 17.659

2.  Follow-up of pregnancy in acromegalic women: different presentations and outcomes.

Authors:  A Atmaca; S Dagdelen; T Erbas
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-03       Impact factor: 2.949

3.  Placental and pituitary growth hormone secretion during pregnancy in acromegalic women.

Authors:  A Beckers; A Stevenaert; J M Foidart; G Hennen; F Frankenne
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

Review 4.  Pregnancy and other pituitary disorders (including GH deficiency).

Authors:  Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-12       Impact factor: 4.690

5.  Menstrual irregularity in women with acromegaly.

Authors:  G A Kaltsas; J J Mukherjee; P J Jenkins; M A Satta; N Islam; J P Monson; G M Besser; A B Grossman
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

6.  Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly.

Authors:  José Leon-Carrion; Juan Francisco Martin-Rodriguez; Ainara Madrazo-Atutxa; Alfonso Soto-Moreno; Eva Venegas-Moreno; Elena Torres-Vela; Pedro Benito-López; Maria Angeles Gálvez; Francisco J Tinahones; Alfonso Leal-Cerro
Journal:  J Clin Endocrinol Metab       Date:  2010-06-16       Impact factor: 5.958

Review 7.  Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature.

Authors:  Sonia Cheng; Ludovica Grasso; Jose A Martinez-Orozco; Rany Al-Agha; Rosario Pivonello; Annamaria Colao; Shereen Ezzat
Journal:  Clin Endocrinol (Oxf)       Date:  2012-02       Impact factor: 3.478

8.  Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly.

Authors:  Mark R Postma; Romana T Netea-Maier; Gerrit van den Berg; Jens Homan; Wim J Sluiter; Margreet A Wagenmakers; Alfons C M van den Bergh; Bruce H R Wolffenbuttel; Ad R M M Hermus; André P van Beek
Journal:  Eur J Endocrinol       Date:  2012-01-16       Impact factor: 6.664

Review 9.  Estrogen regulation of growth hormone action.

Authors:  Kin-Chuen Leung; Gudmundur Johannsson; Gary M Leong; Ken K Y Ho
Journal:  Endocr Rev       Date:  2004-10       Impact factor: 19.871

10.  Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition.

Authors:  Pauline Brummelman; Janneke Koerts; Robin P F Dullaart; Gerrit van den Berg; Oliver Tucha; Bruce H R Wolffenbuttel; André P van Beek
Journal:  Eur J Clin Invest       Date:  2012-10-20       Impact factor: 4.686

View more
  3 in total

1.  Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center.

Authors:  Sema Ciftci Dogansen; Seher Tanrikulu; Gulsah Yenidunya Yalin; Sema Yarman
Journal:  Endocrine       Date:  2018-02-05       Impact factor: 3.633

Review 2.  First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly.

Authors:  Magaly Vialon; Solange Grunenwald; Céline Mouly; Delphine Vezzosi; Antoine Bennet; Philippe Caron
Journal:  Endocrine       Date:  2020-07-30       Impact factor: 3.633

Review 3.  Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.

Authors:  Renato Cozzi; Maria R Ambrosio; Roberto Attanasio; Alessandro Bozzao; Laura De Marinis; Ernesto De Menis; Edoardo Guastamacchia; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Pietro Maffei; Maurizio Poggi; Vincenzo Toscano; Michele Zini; Philippe Chanson; Laurence Katznelson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.